Daniel Apel's most recent trade in Arrowhead Pharmaceuticals Inc. was a trade of 8,730 Common Stock done at an average price of $71.9 . Disclosure was reported to the exchange on April 22, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arrowhead Pharma Inc | Daniel Apel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 71.92 per share. | 22 Apr 2026 | 8,730 | 162,905 (0%) | 0% | 71.9 | 627,862 | Common Stock |
| Arrowhead Pharma Inc | Daniel Apel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 70.11 per share. | 22 Apr 2026 | 3,208 | 172,792 (0%) | 0% | 70.1 | 224,913 | Common Stock |
| Arrowhead Pharma Inc | Daniel Apel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 70.45 per share. | 22 Apr 2026 | 1,157 | 171,635 (0%) | 0% | 70.5 | 81,511 | Common Stock |
| Arrowhead Pharma Inc | Daniel Apel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 75,000 | 176,200 (0%) | 0% | 0 | Common Stock |